SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest long-term Week 40 Phase 3 data, which demonstrates deepening clinical efficacy and reinforces the company's best-in-class potential for treating Hidradenitis Suppurativa. The community is actively discussing the drug's regulatory pathway toward a BLA submission and the potential for a strategic buyout, while simultaneously debating market maker activity and recent analyst upgrades that have significantly raised price targets.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending following a series of significant Department of Defense and defense-contractor awards, which have sparked intense community debate over the company's long-term production scalability and balance sheet health. While bulls point to these mission-critical manufacturing contracts as validation of the company's technology, short-sellers and skeptical investors remain focused on ongoing cash burn concerns and the potential for future equity dilution.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae ($FNMA) is seeing intense trading activity as investors react to ongoing speculation about an exit from conservatorship, with prominent figures like Bill Ackman and Michael Burry reportedly maintaining long positions. Community sentiment remains deeply divided, with bulls pointing to potential future catalysts and institutional buying, while bears emphasize the lack of concrete news and the stock's recent volatility.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is generating significant market interest following a series of operational and financial milestones, including strong cash margins and the securing of long-term offtake agreements. Investors are actively debating the company's growth thesis and debt reduction progress, while recent momentum has been bolstered by increased lithium demand visibility and broader sector excitement regarding energy storage and electrification.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is facing intense community debate as investors weigh concerns over potential dilution and future stock splits against optimism surrounding the commercial traction and insurance coverage expansion of their lead product, Tonmya. While some shareholders are selling amid downward price pressure and a history of capital raises, others are aggressively buying the dip, citing strong long-term pipeline fundamentals and recent insider share purchases as evidence of an impending turnaround.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is facing intense downward pressure driven by a combination of geopolitical instability in the Middle East and market FUD surrounding Google's new memory-compression technology. While the community remains deeply divided between those viewing the current valuation as a generational buying opportunity and those fearing further technical breakdowns, investors are closely watching key support levels as they navigate the disconnect between the company's strong fundamentals and persistent institutional selling.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Alaska Air Group is currently at the center of investor focus following a Q1 guidance revision that widened projected losses, driven by fuel cost headwinds and operational challenges in Hawaii and Mexico. Despite the near-term volatility, the community is actively debating the stock's valuation, highlighting its strategic positioning, long-term growth prospects, and recent heavy institutional accumulation as indicators that the shares may be undervalued.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is currently rallying as investors position the stock as a primary 'bring-your-own-power' solution for the surging AI data center buildout, further fueled by recent policy discussions surrounding energy infrastructure independence. The community is actively debating the stock's valuation and volatility, while tracking technical breakout levels and watching for institutional accumulation as the company solidifies its role in the critical power generation sector.

Alcoa Corp. engages in the bauxite mining, alumina refining, and aluminum smelting and casting. It operates through the Alumina and Aluminum segments. The Alumina segment consists of a refining system, including the mining of bauxite, which is then refined into alumina, a compound of aluminum and oxygen that is the raw material used by smelters to produce aluminum metal. The Aluminum segment is composed of smelting and casthouse system. The company was founded by Charles Martin Hall on July 9, 1886 and is headquartered in Pittsburgh, PA.

Alcoa Corp

Alcoa is trending as investors weigh the impact of new U.S. metal tariffs, creating significant debate over whether the policy provides domestic support or threatens profit margins through higher import costs. Community discourse is heavily focused on the stock's volatility and its long-term potential as a key player in critical infrastructure and data center construction.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as the community debates its future following a major strategic shift to discontinue its Aortic Valve Systems, which has sparked discussions about potential impact on long-term margins and resource allocation. Meanwhile, investors are closely monitoring the stock's resilient momentum and recent bullish analyst outlooks that emphasize strong growth in the company's cardiovascular and electrophysiology segments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AMRN 

NVS buys another biotech not named Amarin

https://cnb.cx/3PMq97X

Ron Veres

Wikthor

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

CNBC

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

$AMRN Way too early. Novartis keeps buying but Amarin’s biggest repricing variables are still directly ahead. EMT2, LR USPTO FOA, and Hikma/SCOTUS clarity materially change what a buyer will be forced to pay versus today&#39;s value. Roughly speaking, EMT2 can add anywhere from $0.4B–$2.0B+ depending on how strong/clean the data are, LR can add $0.3B–$1.5B+ depending on survivability/reset path via impending first office action (due any day), and legal clarity with SCOTUS (by June) can shrink the discount/escrow excuse. Amarin is cleaner operationally, cash flowing, debt free, and harder to lowball than it was a year ago (buyer finally has leverage). Sarissa’s job is not to sell early just because Novartis is actively buying companies. Their investment thesis and MO is to maximize exit price. Selling a cleaned-up asset right before the looming catalyst stack matures/tightens up the final evaluation range and lifts the floor would be negotiating stupidly against itself.

StockTwits Web

StockTwits For Android 

Amarin Corp - ADR

 

NVS buys another biotech not named Amarin



declanaidan

@declanaidan 

You’re correct. My personal opinion from the past history is that even if Vascepa cures cancer, BO is not easy for Amarin because of two main things only:

1) Management is demanding too much from the buyer or
2) Management should show profits/ or a sign for wealth generation / positive EPS/ sufficient free cash flow for a potential dividend etc…

IMHO we may fall under point 2 above and hopefully longs may see some relief by 2Q or 3Q to ramp up it’s SP

GL

GreenTurtle

StockTwits for iOS

 

You’re correct. My personal opinion from the past history is that even if Vascepa cures cancer, BO is not easy for Amarin because of two main things only:

1) Management is demanding too much from the buyer or
2) Management should show profits/ or a sign for wealth generation / positive EPS/ sufficient free cash flow for a potential dividend etc…

IMHO we may fall under point 2 above and hopefully longs may see some relief by 2Q or 3Q to ramp up it’s SP

GL

BobGood

@declanaidan we don’t want to be bought out yet. Don’t you understand that yet regarding Lr-etepa?

 we don’t want to be bought out yet. Don’t you understand that yet regarding Lr-etepa?